Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,630 | 4,069 | 13,907 | 24,002 | 17,225 |
| TOTAL | $3,172 | $5,203 | $15,581 | $26,022 | $17,756 |
| Non-Current Assets | |||||
| Intangibles | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 |
| Other Non-Current Assets | 1,133 | 969 | 1,071 | 1,168 | 1,273 |
| TOTAL | $3,047 | $2,883 | $2,985 | $3,082 | $3,187 |
| Total Assets | $6,219 | $8,086 | $18,566 | $29,104 | $20,943 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 5,639 | 4,340 | 3,734 | 3,099 | 8,857 |
| Accrued Expenses | 7,650 | 6,929 | 6,240 | 6,485 | 6,286 |
| Other current liabilities | N/A | N/A | 3,000 | 5,500 | N/A |
| TOTAL | $13,735 | $11,735 | $13,421 | $15,511 | $15,515 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 460 | 178 | 302 | 424 | 577 |
| TOTAL | $460 | $178 | $302 | $424 | $577 |
| Total Liabilities | $14,195 | $11,913 | $13,723 | $15,935 | $16,092 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 56,268 | 32,062 | 28,348 | 28,348 | 28,303 |
| Common Shares | 3 | 3 | 3 | 3 | 2 |
| Retained earnings | -217,244 | -209,108 | -199,841 | -191,001 | -179,904 |
| TOTAL | $-7,976 | $-3,827 | $4,843 | $13,169 | $4,851 |
| Total Liabilities And Equity | $6,219 | $8,086 | $18,566 | $29,104 | $20,943 |